Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

Abstract Background The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheumatoid arthritis (RA) with an inadequate response...

Full description

Bibliographic Details
Main Authors: Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K. Mangan, Gerd R. Burmester
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Sarilumab
Interleukin-6
Adalimumab
csDMARDs
Methotrexate
Online Access:http://link.springer.com/article/10.1186/s13075-020-02194-z

Internet

http://link.springer.com/article/10.1186/s13075-020-02194-z

Similar Items